- CFO Spotlights
- Profiles
- John Smither
Profile
John Smither
Chief Financial Officer and principal financial officer, MBX Biosciences, Inc.
In the seat. First published here October 28, 2026; built from records as of October 28, 2026.
John Smither has been Chief Financial Officer and principal financial officer of MBX Biosciences, Inc. since July 13, 2026, according to the company's filing of July 13, 2026.1
The filing gives John Smither's previous role as interim Chief Financial Officer at MBX Biosciences, Inc.1 John Smither already worked at MBX Biosciences, Inc. when appointed, so the record counts the move as an internal promotion.1 The filing shows an earlier chief financial officer seat, so this is not John Smither's first.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| MBX Biosciences, Inc. (MBX) Pharmaceutical Preparations | Chief Financial Officer and principal financial officer | In the seat |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- July 13, 2026effective
MBX Biosciences, Inc. appointed John Smither as Chief Financial Officer and principal financial officer, effective July 13, 2026.
On July 9, 2026, the Board appointed John Smither, the Company’s current interim Chief Financial Officer, as Chief Financial Officer and principal financial officer of the Company, effective as of July 13, 2026.
[1] Filing by MBX Biosciences, Inc., filed with the SEC on July 13, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, MBX Biosciences, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 13, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or John Smither wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.